SCHEMBL2392941

SCHEMBL2392941

CC12CCCc3cc(C(=O)Nc4ccc(C(=O)O)c(O)c4)cc(c31)CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
PKM P14618 1/20 0.54
LY96 Q9Y6Y9 1/20 0.45
SIRT6 Q8N6T7 1/20 0.45
RARA P10276 3/20 0.43
RARB P10826 3/20 0.43
RARG P13631 2/20 0.43
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
EPHX2 P34913 1/20 0.41
MEN1 O00255 3/20 0.41
CYP26A1 O43174 1/20 0.41
PGR P06401 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2390930 0.89 SMN1; SMN2 (0.50) KMT2APKMLY96RARARARB
SCHEMBL2398306 0.88 RARA (0.58) KMT2ALY96RARARARBRARG
SCHEMBL2394385 0.88 CPT2 (0.44) KMT2APKMLY96RARARARB
SCHEMBL2398289 0.86 NPC1 (0.45) KMT2ARARARARBRARGRAB9A
SCHEMBL2394957 0.84 MEN1 (0.54) KMT2ALY96RARARARBRARG
SCHEMBL2394316 0.79 RARA (0.46) KMT2ALY96RARARARBRARG
SCHEMBL2393263 0.79 SMN1; SMN2 (0.43) KMT2ALY96RARARARBRARG
SCHEMBL2394352 0.79 NPC1 (0.45) KMT2ARARARARBRARGRAB9A
SCHEMBL2397423 0.79 KMT2A (0.60) KMT2APKMLY96SIRT6RAB9A
SCHEMBL2396642 0.79 P4HTM (0.53) RARARARBRAB9ANPC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG KMT2A 1560/4885PKM 2418/4885LY96 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.